~~<i id='01F3D774F3'><strike id='01F3D774F3'><tt id='01F3D774F3'><pre id='01F3D774F3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：fashion 2025-10-01 15:40:14 - browse：7

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： WATCH: Why do our ears pop?

explore

hotspot

focus

knowledge

hotspot

AdobeSonataTherapeutics,astartupcreatedtwoyearsagothroughthemergeroftwoFlagshipPioneeringcompanies,h

WSS

Weight bias in eating disorder treatment complicated by new weight loss drugs

Congress may force more Covid

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Paxlovid study fails to answer questions over benefit for broader groups

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

As AI regulations shape up, health tech startups beg for clarity

hotspot

knowledge

explore

At least 13 dead in Texas as scorching temps continue

Elevance, SCAN deals highlight health insurer acquisition scrutiny

State Dept. review finds Biden bears some blame for Afghanistan failures

In 'major milestone,' FDA approves first cell therapy for solid tumors

Medicare details structure of new drug price negotiation program

Ask STAT: What do you want to know about ChatGPT in medicine?

After affirmative action ruling, medical educators look to 'holistic review'

Hospitals are piloting generative AI tools as regulators play catch

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Opioid cravings were reduced by anti

explore

In 'major milestone,' FDA approves first cell therapy for solid tumors

Why are elite athletes different? Take a look at their microbes

Opioid cravings were reduced by anti

The battle over the Brookhaven Landfill on Long Island

Congress may force more Covid

Weight loss drugs aren’t covered by Obamacare. That may change

hotspot

focus

knowledge

hotspot